

(D)-PPA 1

Cat. No.:	HY-P4072
CAS No.:	1620813-53-7
Molecular Formula:	C ₇₀ H ₉₈ N ₂₀ O ₂₁
Molecular Weight:	1555.65
Sequence:	D-{Asn-Tyr-Ser-Lys-Pro-Thr-Asp-Arg-Gln-Tyr-His-Phe}
Sequence Shortening:	D-{NYSKPTDRQYHF}
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity of 0.51 μM with in vitro and in vivo efficacy ^[1] .								
In Vitro	<p>(D)-PPA 1 (0.2 mg/mL, 1.0 mg/mL) blocks the interaction between PD-1/PD-L1 at 1.0 mg/mL^[1]. (D)-PPA 1 (3.125-100 μM; 24 h, 48 h) doesn't kill tumor cells directly with no affect on CT26 cells growth^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table> <tr> <td>Cell Line:</td> <td>CT26 cells</td> </tr> <tr> <td>Concentration:</td> <td>3.125, 6.25, 12.5, 25, 50, and 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours, 48 hours</td> </tr> <tr> <td>Result:</td> <td>Left tumor cells growing normally.</td> </tr> </table>	Cell Line:	CT26 cells	Concentration:	3.125, 6.25, 12.5, 25, 50, and 100 μM	Incubation Time:	24 hours, 48 hours	Result:	Left tumor cells growing normally.
Cell Line:	CT26 cells								
Concentration:	3.125, 6.25, 12.5, 25, 50, and 100 μM								
Incubation Time:	24 hours, 48 hours								
Result:	Left tumor cells growing normally.								
In Vivo	<p>(D)-PPA 1 (2 mg/kg; s.c. or i.p.; once daily for 7 d) inhibits CT26 tumor growth in vivo in mice^[1]. (D)-PPA 1 (40 μg/mouse in 200 μL; i.v.; single dose) has the ability to target to tumor tissue in CT26-tumor-bearing mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td> <td>CT26-tumor-bearing Balb/c mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>1) Subcutaneous injection, for around the tumor once every day for 7 days 2) Intraperitoneal injection, once every day for 7 days3) Intraperitoneal injection, once every day for 12 days; recorded the survival on day 13</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth, and prolonged the survival in mice.</td> </tr> </table>	Animal Model:	CT26-tumor-bearing Balb/c mice ^[1]	Dosage:	2 mg/kg	Administration:	1) Subcutaneous injection, for around the tumor once every day for 7 days 2) Intraperitoneal injection, once every day for 7 days3) Intraperitoneal injection, once every day for 12 days; recorded the survival on day 13	Result:	Inhibited tumor growth, and prolonged the survival in mice.
Animal Model:	CT26-tumor-bearing Balb/c mice ^[1]								
Dosage:	2 mg/kg								
Administration:	1) Subcutaneous injection, for around the tumor once every day for 7 days 2) Intraperitoneal injection, once every day for 7 days3) Intraperitoneal injection, once every day for 12 days; recorded the survival on day 13								
Result:	Inhibited tumor growth, and prolonged the survival in mice.								

REFERENCES

[1]. Chang HN, et al. Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. *Angew Chem Int Ed Engl.* 2015 Sep 28;54(40):11760-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA